IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks.
At Snapdragon Chemistry, now part of Cambrex, our chemists specialize in creating custom solutions and technologies to take on your toughest process development and production challenges. This includes expertise in designing and building reactors that enable seamless technology transfer as a process scales up for commercial manufacturing.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
Cambrex offers a comprehensive suite of testing services for complex biopharmaceuticals including standalone analytical R&D, method validation, release testing, ICH stability, and routine QC testing.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex offers extensive development services tailored to meet your drug product needs in early development. From pre-formulation to Phase II, we ensure your products are developed with speed, flexibility, and quality in mind.
Whether you need rapid development, flexible manufacturing solutions, or high-quality production, Cambrex is your trusted partner for advancing your drug product from concept to the clinic.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
02.09.2021
Waltham, MA – February 9, 2021 – The US Defense Advanced Research Project Agency (DARPA) has selected Snapdragon Chemistry, Inc., for a $1.5-million grant to develop continuous technology for US-based manufacturing, a deal that will help secure the domestic supply chain and provide cost-savings for pharmaceuticals in the United States. Snapdragon is using the grant money to develop its highly automated continuous manufacturing platform to convert chemicals into valuable starting materials for pharmaceutical manufacturing.
“We are thrilled to be selected by DARPA to further our development efforts,” said Matthew Bio, President, and CEO of Snapdragon Chemistry. “This grant will allow us to bring together expertise in automation and continuous manufacturing to create a platform technology for the manufacture of pharmaceutical intermediates and fine chemicals. We expect this technology will become a key component of a secure national supply chain for the chemical components critical to health and human welfare.”
Snapdragon CSO, Dr. Eric Fang commented: “DARPA has been at the forefront of funding the most cutting-edge technologies that have changed the world. The DARPA grant will facilitate our development of next-generation continuous flow manufacturing technology for flexible, on-demand production of a diverse set of vitally important fine chemical building blocks from commodity chemicals with far less waste compared with the existing ‘dirty chemistry’ that was originally developed in the late 19th century.
The grant includes development funding over the next 24 months, with additional funding for the commercialization of the concept in the subsequent 12 months. R&D will focus on the design of a programmable platform manufacturing system able to process commodity feedstocks into high-value functionalized building blocks.
The technology platforms developed in-house by Snapdragon and enhanced by the DARPA grant will help usher in a new era of chemistry and pharmaceutical production.
About Snapdragon Chemistry Snapdragon Chemistry specializes in active pharmaceutical ingredient (API) batch and continuous flow process development, utilizing state-of-the-art automation technology and proprietary equipment to solve complex process and analytical development challenges. With R&D and manufacturing headquartered in Waltham, Massachusetts, Snapdragon’s 70+ employees come with strong ties to the local scientific community, with 31 PhD scientists on staff. For more information, please contact info@snapdragonchemistry.com.